恶性肿瘤患者血清VEGF、IL-8水平与化疗疗效关系的研究

探讨血管内皮生长因子(VEGF)、白介素-8(IL-8)水平与恶性肿瘤临床分期、组织学分型等因素及化疗近期疗效之间的关系.采用定量ELISA方法分别检测53例恶性肿瘤患者化疗前血清VEGF与IL-8水平,其中25例经正规化疗后复查上述指标;10例对照为健康志愿者;同期还有CEA、CA125及CYFRA21-1或CEA及CA19-9两种肿瘤标志物组合检测.恶性肿瘤组化疗前血清VEGF及IL-8含量均明显高于对照组(P＜ 0.01),且随临床分期的进展而上升,但与肿瘤组织学类型及性别无明显相关性.化疗后血清VEGF及IL-8均显著下降(P＜ 0.01).VEGF、IL-8诊断肿瘤的阳性率高于瘤标组合并随临床分期进展而上升,联合检测可提高阳性率.VEGF和IL-8是肿瘤的发生、发展和转移的有效生物学指标.动态检测VEGF和IL-8化疗前后浓度变化能在一定程度上反映化疗近期疗效,可为临床选择治疗措施及判断预后提供有效帮助.

The Investigation of Relationship Between Chemotherapeutic Response and Changes of Serum Vascular Endothelial Growth Factor and Interleukin-8 in Patients with Malignant Tumor

To investigate the relationship between the changes of the serum vascular endothelial growth factor(VEGF),interleukin-8(IL-8) and staging,differentiation and chemotherapeutic response in patients with malignant tumor,the serum VEGF,IL-8 levels and two tumor mark combination(CEA,CA125 and CYFRA21-1 or CEA and CA199) were measured by ELISA in 53 patients with malignant tumor before chemotherapy.The serum VEGF and IL-8 levels were measured again in 25 patients after chemotherapy and 10 healthy controls.The results showed that the serum VEGF and IL-8 levels in cancer patients before chemotherapy were significantly higher than those in controls.Moreover,they were significantly increased in stage IV patients compared with stage II and stage III patients,but there is no correlation with the differentiation and sex.The positive rates in diagnosing carcinoma with serum VEGF and IL-8 level were higher than those with tumor mark combination,while the positive rate can be increased by measuring serum VEGF,IL-8 and tumor mark combination together.The serum VEGF and IL-8 levels were useful biological marks in the diagnosis of recurrence and metastasis.The changes of serum VEGF and IL-8 levels in patients before and after chemotherapy can reflect the therapeutic effect and may be useful in clinical decision and predicting prognosis.